18F-fluorothymidine - Merck

Drug Profile

18F-fluorothymidine - Merck

Alternative Names: 18F-FLT (3'-deoxy-3'[18F]-fluorothymidine) - Merck; 18F-FLT - Merck; 18F-FLT-PET - Merck

Latest Information Update: 27 Jul 2015

Price : $50

At a glance

  • Originator Merck & Co
  • Class Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 27 Dec 2011 Merck completes a phase II trial in Breast cancer (diagnosis) in USA and South Korea (NCT01015131)
  • 02 Jul 2011 Merck completes enrolment in its phase II trial for Breast cancer (diagnosis) in USA and South Korea (NCT01015131)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top